Recent Updates
Recently added Catalysts
CRIS Neutral Sentiment

Mt Sinai Comprehensive Cancer Center

Key Takeaway: The article provides an overview of the Mt Sinai Comprehensive Cancer Center, detailing its management, collaborations, patient studies, and pipeline of treatments. It highlights various sponsored studies including TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL, along with an overview of their drug pipeline featuring Emavusertib and Fimepinostat. The content serves as a resource for investors and patients alike.
Price reaction · baseline $20.2 (2026-03-04T16:02:00.000Z) · hit during market hours · clean, no other CRIS news in the window
day 0 close · peak
+2%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~1 mo
High dilution risk
Lead asset
Emavusertib
Phase 2 · Chronic Lymphocytic Leukemia

Full Press Release Details

• About Company Overview Management Board of Directors Advisory Boards
• Collaborations Partner Collaborations Scientific & Research Collaborations
• Patients Patients Overview Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL Understanding Primary CNS Lymphoma Compassionate Use Policy
• Pipeline Pipeline Overview Emavusertib (CA-4948) Fimepinostat CA-170 CA-327
• Scientific Resources
• Investors Overview Press Releases Events and Presentations Corporate Governance Committee Composition Contact the Board Financial Information SEC Filings Annual Reports IRS Form 8937 Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage Contact Us
• Careers Life at Curis Open Positions Benefits
• Contact
• Company Overview
• Management
• Board of Directors
• Advisory Boards
• Partner Collaborations
• Scientific & Research Collaborations
• Patients Overview
• Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• Understanding Primary CNS Lymphoma
• Compassionate Use Policy
• Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• TakeAim Lymphoma
• TakeAim Leukemia
• TakeAim CLL
• Pipeline Overview
• Emavusertib (CA-4948)
• Fimepinostat
• CA-170
• CA-327
• Overview
• Press Releases
• Events and Presentations
• Corporate Governance Committee Composition Contact the Board
• Financial Information SEC Filings Annual Reports IRS Form 8937
• Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage
• Contact Us
• Committee Composition
• Contact the Board
• SEC Filings
• Annual Reports
• IRS Form 8937
• Interactive Chart
• Historical Stock Lookup
• Analyst Coverage
• Life at Curis
• Open Positions
• Benefits

Frequently Asked Questions

What studies are sponsored by Mt Sinai Cancer Center?

The center sponsors studies like TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL.

What drugs are included in the pipeline?

The pipeline includes Emavusertib (CA-4948), Fimepinostat, CA-170, and CA-327.

Who manages the Mt Sinai Comprehensive Cancer Center?

The center is managed by a board of directors and advisory boards.

What is the focus of the TakeAim studies?

The TakeAim studies focus on specific types of lymphoma and leukemia.

Last updated: Mar 4, 2026